Renal angiomyolipoma
The EU has approved 1 indication of 1 drug in renal angiomyolipoma. None of them needs a biomarker result.
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| No biomarker required1 | ||||
Votubia | None | Monotherapy | Any line | Tuberous sclerosis complex; at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery |
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Everolimus (Votubia)
Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with TSC who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.